Provigil is a brand-name medication that contains modafinil as its active ingredient. It is classified as a wake-promoting agent within the field of neurology and is available in pill form in two strengths: 100 mg and 200 mg. In Hong Kong, Provigil is a prescription-only product regulated by the Department of Health. The medication is marketed for the treatment of excessive daytime sleepiness associated with specific sleep-wake disorders.
Modafinil promotes wakefulness through several neurochemical pathways:
These actions together raise the brain’s overall level of alertness without producing the pronounced euphoria or motor stimulation typical of traditional stimulants. Onset of effect usually occurs within 30-60 minutes, peaks around 2-4 hours, and the clinical effects can last 10-12 hours, reflecting modafinil’s relatively long half-life (≈12-15 hours).
Provigil is FDA- and EMA-approved for, and therefore commonly prescribed in Hong Kong to treat, the following conditions:
The medication is intended for adult patients (≥ 18 years) who experience significant functional impairment due to daytime sleepiness. It is not approved for general fatigue or for use as a cognitive enhancer.
Research literature has explored several off-label applications of modafinil. When such use is considered, it must be under strict medical supervision and in accordance with local regulations.
Off-label use requires individualized risk assessment and close monitoring by a qualified healthcare provider.
Patients should disclose all prescription medications, over-the-counter drugs, supplements, and herbal products before initiating Provigil.
All dosing decisions must be individualized by a prescribing clinician.
This article provides educational information about Provigil and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Modafinil has been studied for off-label cognitive enhancement, but robust evidence supporting consistent academic benefit is lacking. Use for this purpose is not approved and may carry risks that outweigh uncertain gains.
Provigil is a prescription medication; travelers should carry the original prescription label, a copy of the prescribing doctor’s note, and declare the medication at customs if required by the destination country.
Standard drug screens typically do not target modafinil, but some specialized panels may detect it. Employees should inform potential employers of legitimate prescription use in advance.
Both contain the same active ingredient, modafinil, in identical strengths. Differences may lie in inactive excipients, tablet imprint, and brand-specific manufacturing standards, which generally do not affect clinical efficacy.
Caffeine can add to the stimulant effects of modafinil, potentially increasing nervousness or insomnia. Moderate caffeine intake is usually tolerated, but patients should monitor personal sensitivity.
Tablets are stable until the expiration date when kept in their original container at room temperature. Once the container is opened, the medication remains effective provided it is stored as directed.
Modafinil has a lower abuse potential compared to classic stimulants, and physical dependence is uncommon. Nonetheless, psychological reliance can develop in some individuals, so use should be regularly reviewed by a clinician.
Discontinue the medication immediately and seek urgent medical care, as this could represent a serious hypersensitivity reaction requiring prompt treatment.
No direct pharmacological interaction has been identified. However, if you have an active infection or fever, discuss timing with your healthcare provider to ensure optimal immune response.
Combining Provigil with other central nervous system stimulants or wake-promoting agents is generally discouraged due to additive effects. If a patient requires treatment for both insomnia and excessive daytime sleepiness, a careful, coordinated plan should be developed by the prescribing clinician.